Please login to the form below
Hyperion
This page shows the latest Hyperion news and features for those working in and with pharma, biotech and healthcare.
Horizon swoops on Raptor to add rare disease products
Horizon became an Irish company after buying Vidara Therapeutics in 2014 in a tax-inversion deal, and in 2015 also snapped up Hyperion Therapeutics for $1.1bn, taking control of urea
Latest news
-
Rebuffed Horizon tries to replace Depomed board members
Since acquiring Vidara, Horizon has also bought Hyperion Therapeutics in a $1.1bn deal signed earlier this year.
-
Horizon launches $3bn hostile bid for Depomed
It is offering $29.25 per share for Depomed, a 42% premium over the company's closing share price on Tuesday, having already snapped up Hyperion Therapeutics for $1.1bn earlier
-
Shire rumoured to be pursuing Actelion
Other transactions including rare disease companies of late include Horizon Pharma's $1.1bn deal to buy urea cycle disorder specialist Hyperion Therapeutics and BioMarin $840m purchase of Prosensa in order
-
Alexion boosts rare disease portfolio with $8.4bn Synageva buy
Meanwhile, Horizon Pharma stumped up $1.1bn for urea cycle disorder specialist Hyperion Therapeutics and BioMarin bought Prosensa for $840m, gaining access to its muscular dystrophy drug drisapersen. .
-
FDA clears Hyperion's Ravicti for urea cycle disorders
Hyperion has been given the go-ahead by the FDA to market Ravicti for the treatment of patients aged two years or over. ... News of the approval led to a 33 per cent surge in Hyperion's share price to $21.05, well above its 52-week high of $16.48.
More from news
Approximately 2 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Medius Deal Watch table for March 2015
1, 200. Hyperion / Horizon. Company acquisition. 2 marketed urea cycle disorder orphan drugs in the US.
-
Pharma deals in March 2015
Covis (asset). Concordia. 1.2. 8.2. NR. Hyperion. Horizon. 1.1. 9.6. 35%. ... But, Hyperion has $70m in operating costs and Horizon expects to make synergy savings of $50m.
-
Deal Watch table for April 2014
600. Andromeda Biotech/ Hyperion Therapeutics. Acquisition. DiaPep277 24-amino acid peptide derived from human heat shock protein 60 (hsp60) to treat T1DM (p3).
-
Pharma deals during April 2014
Mallinckrodt, Ranbaxy Laboratories/ Sun Pharmaceuticals; Silom Medical Company/ Actavis), Pharmaceuticals/Biologics (Furiex/ Forest Laboratories, Andromeda Biotech/ Hyperion Therapeutics), OTC (Insight Pharmaceuticals/ Prestige Brands), Diagnostics
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
Medgenics confirms appointment of Dr Marvin Garovoy
His industry experience includes stints at Genentech, Xoma Corporation, and Hyperion Therapeutics, while his medical careers has also seen him serve as professor of surgery, medicine and laboratory medicine at the
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s RSV vaccine approved by FDA for older adults
No results were found
PMHub
Springer Nature
Operating in 50+ countries, we’re a leading research, educational, and professional publisher dedicated to advancing scientific discovery. Whether you’re looking...
Latest intelligence
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
- Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
- Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...
